Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 414,832 | -224,060 | -329,668 | 238,616 | 523,367 |
| Depreciation Amortization | 638,696 | 629,471 | 552,483 | 278,253 | 370,156 |
| Income taxes - deferred | -260,217 | -292,251 | 69,198 | -136,937 | -236,610 |
| Accounts receivable | -51,883 | -90,135 | -92,735 | -38,647 | -92,326 |
| Accounts payable and accrued liabilities | 9,603 | -11,225 | 57,021 | -18,935 | 4,770 |
| Other Working Capital | -204,439 | 9,905 | -47,952 | -85,437 | -154,173 |
| Other Operating Activity | 545,415 | 1,250,272 | 570,160 | 662,735 | 361,217 |
| Operating Cash Flow | $1,092,007 | $1,271,977 | $778,507 | $899,648 | $776,401 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -120,100 | -1,036 | 1,068,181 | -642,675 | 67,900 |
| PPE Investments | -23,962 | -29,046 | -27,641 | -15,004 | -25,926 |
| Net Acquisitions | N/A | 53,000 | -6,234,792 | 14,259 | -55,074 |
| Purchase Sale Intangibles | -19,000 | -469,148 | -17,891 | -364,250 | -142,200 |
| Other Investing Activity | -19,000 | -469,148 | -17,891 | -364,250 | -142,200 |
| Investing Cash Flow | $-163,062 | $-446,230 | $-5,212,143 | $-1,007,670 | $-155,300 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 0 | 0 | 5,191,463 | 1,481,381 | 0 |
| Debt Repayment | -31,000 | -582,014 | -1,320,600 | -889,575 | -33,387 |
| Common Stock Issued | 46,459 | 98,020 | 135,261 | 99,681 | 57,831 |
| Common Stock Repurchased | -269,761 | -54 | 0 | -146,537 | -301,450 |
| Other Financing Activity | -50,952 | -45,443 | -35,602 | -16,877 | -16,739 |
| Financing Cash Flow | $-305,254 | $-529,491 | $3,970,522 | $528,073 | $-293,745 |
| Exchange Rate Effect | 1,137 | -6,222 | -3,207 | 374 | 366 |
| Beginning Cash Position | 881,482 | 591,448 | 1,057,769 | 637,344 | 309,622 |
| End Cash Position | 1,506,310 | 881,482 | 591,448 | 1,057,769 | 637,344 |
| Net Cash Flow | $624,828 | $290,034 | $-466,321 | $420,425 | $327,722 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,092,007 | 1,271,977 | 778,507 | 899,648 | 776,401 |
| Capital Expenditure | -23,962 | -29,046 | -27,641 | -15,004 | -40,135 |
| Free Cash Flow | 1,068,045 | 1,242,931 | 750,866 | 884,644 | 736,266 |